This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Renal damage associated with multiple myeloma

Authoring team

Renal damage is a common and potentially serious complication of myeloma:

  • around 20-25% of patients with multiple myeloma presents with renal impairment while 50% of patients will have it sometime during their illness
  • reversal of renal impairment can be achieved in around 50% of the patients but the remaining patients will have some degree of renal insufficiency out of which 2-12% will require renal replacement therapy (1)

The principle mechanism for the renal damage associated with multiple myeloma is the damage caused to renal tubules by free light chains (cast nephropathy, or “myeloma kidney”)

  • the risk of renal damage is directly proportionate to the level of urinary free light chain excretion
  • it is not associated with light chain class or the presence or absence of whole M-proteins
  • around 2% of patients without urinary free light chain have renal insufficiency while this figure increases to 50% with higher levels of urinary free light chain excretion (1)

Other possible pathogenic mechanisms include:

  • haemodynamic factors may cause ischaemic renal damage especially in the elderly
  • hypercalcaemia
  • hyperuricaemia
  • amyloidosis
  • ureteric obstruction

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.